Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nyse  >  Merck and Company    MRK

MERCK AND COMPANY (MRK)
Mes dernières consult.
Most popular
  Report  
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsofficial PublicationsSector newsTweets
OFFRE ETE Zonebourse : Jusqu'à 6 mois offerts sur tous les portefeuilles
Sector news Pharmaceuticals - NEC
06/20GILEAD SCIENCES : GSK takes billion-dollar drug fight with Gilead to top AIDS me..
RE
06/20Roche to Buy Rest of Cancer Firm -- WSJ
DJ
06/20SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/20Latecomer Sanofi looks to catch next wave of cancer therapies
RE
06/20Merck KGaA Partners With Alibaba Health in China
DJ
06/19High Times refreshes IPO plans as cannabis companies build buzz on Wall Stree..
RE
06/19MERCK : to Distribute HistoCyte Laboratories Products
DJ
06/19Alexion Uses FDA Priority-Review Voucher for Blood Disorder
DJ
06/19Roche to Pay $2.4 Billion for Full Control of Foundation Medicine -- 2nd Upda..
DJ
06/19Roche pays $2.4 billion for rest of cancer expert Foundation Medicine
RE
06/19PEUGEOT : Sanofi poaches former PSA finance boss Chasseloup de Chatillon
RE
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement -- Update
DJ
06/19SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/19Sanofi Names Jean-Baptiste Chasseloup de Chatillon as CFO, Executive VP
DJ
06/19Roche, Foundation Medicine Reach Definitive Merger Agreement
DJ
06/18How U.S. tax reform rewards companies that shift profit to tax havens
RE
06/18Evotec Shares Jump After It Secures Sanofi Agreement
DJ
06/18Indivior shares rise after U.S. court order blocks generic rival drug
RE
06/18INDIVIOR : Wins Legal Battle; Temporarily Blocks Launch of Generic Drug
DJ
06/18SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/16International fund managers turn to financials, tech as trade worries rise
RE
06/15BAYER : Japan suspends sale of Canadian wheat after GMO wheat found in Alberta
RE
06/15UK's Indivior will fight U.S. FDA's approval for copycat drug
RE
06/15Indivior Shares Drop After U.S. Approves Suboxone Generics
DJ
06/15UK's Indivior to seek injunction after rival gets FDA approval for generics
RE
06/15NOVARTIS : Study Shows Jakavi Reduces Blood Clots, Risk of Death
DJ
06/15Roche's Gazyva Cancer Drug Outperforms MabThera
DJ
06/15NOVARTIS : Cohen Probe Is Extended to Lobbying -- WSJ
DJ
06/15SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/15NOVARTIS : Releases Phase 3 Data for Zessly, Erelzi Biosimilars
DJ
06/14ADRs End Mostly Lower; iQiyi, Unilever Trade Actively
DJ
06/14NOVARTIS : Prosecutors Investigating Michael Cohen for Possible Illegal Lobbying
DJ
06/14ABBOTT LABORATORIES : Allergan appoints former Abbott executive to its board
RE
06/14GLAXOSMITHKLINE : Positive Results for ViiV Healthcare's HIV Studies
DJ
06/14SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/14Roche to Present Ocrevus Data Showing Delayed Wheelchair Need in MS Patients
DJ
06/14FDA Rejects Mylan's Asthma Generic Over Deficiencies -- Market Mover
DJ
06/13Sanofi says on track to regain solid position in cancer drugs
RE
06/13SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/12JOHNSON & JOHNSON : Accepts Platinum Equity's $2.1 Billion Offer for LifeScan Bu..
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials -- Update
DJ
06/12GSK says vaccine business president to leave by year-end
RE
06/12GLAXOSMITHKLINE : Vaccines President to Leave Company by Year-End
DJ
06/12Eli Lilly, AstraZeneca Drop Two Late-Stage Alzheimer's Drug Trials
DJ
06/12AstraZeneca, Eli Lilly to Stop Alzheimer's Treatment Trials
DJ
06/12SHIRE PLC SHIRE PLC : Rule 2.9 Announcement
DJ
06/11Investors ready to resuscitate Johnson & Johnson's ailing stock
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Takeda shareholder group aims to block $62 billion Shire deal
RE
06/11Biotech's Soon-Shiong hiring bankers for Nant cancer drug IPO
RE
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2018 42 072 M
EBIT 2018 13 566 M
Net income 2018 7 224 M
Debt 2018 15 754 M
Yield 2018 3,19%
P/E ratio 2018 23,49
P/E ratio 2019 15,88
EV / Sales 2018 4,27x
EV / Sales 2019 4,07x
Capitalization 164 B
Sector Pharmaceuticals - NEC
1st jan.Capitalization (M$)
MERCK AND COMPANY8.46%164 082
JOHNSON & JOHNSON-13.17%325 398
PFIZER-0.17%211 520
NOVARTIS-8.25%188 977
ROCHE HOLDING LTD.-14.38%182 331
AMGEN5.78%121 721
ABBOTT LABORATORIES10.23%110 135
BAYER-2.22%106 282
GLAXOSMITHKLINE17.20%101 387
SANOFI-4.41%98 673
ELI LILLY AND COMPANY2.87%93 466
ASTRAZENECA4.73%90 289
BRISTOL-MYERS SQUIBB COMPANY-12.45%87 693
NOVO NORDISK A/S-13.90%85 401
ALLERGAN PLC5.87%58 224
CELGENE CORPORATION-25.52%56 341
SHIRE2.00%48 412
JIANGSU HENGRUI MEDICINE CO LTD43.14%43 187
ASTELLAS PHARMA INC21.52%31 115
TAKEDA PHARMACEUTICAL CO LTD-33.82%30 308
CHUGAI PHARMACEUTICAL CO LTD3.99%30 014